Cas:98768-71-9 4-bromo-N-(3-chloropropyl)benzenesulfonamide manufacturer & supplier

We serve Chemical Name:4-bromo-N-(3-chloropropyl)benzenesulfonamide CAS:98768-71-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

4-bromo-N-(3-chloropropyl)benzenesulfonamide

Chemical Name:4-bromo-N-(3-chloropropyl)benzenesulfonamide
CAS.NO:98768-71-9
Synonyms:4-bromo-N-(3-chloropropyl)benzenesulfonamide
Molecular Formula:C9H11BrClNO2S
Molecular Weight:312.61100
HS Code:2935009090

Physical and Chemical Properties:
Melting point:88-90ºC
Boiling point:404.7ºC at 760mmHg
Density:1.558g/cm3
Index of Refraction:1.568
PSA:54.55000
Exact Mass:310.93800
LogP:3.82800

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 4-bromo-N-(3-chloropropyl)benzenesulfonamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-bromo-N-(3-chloropropyl)benzenesulfonamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-bromo-N-(3-chloropropyl)benzenesulfonamide Use and application,4-bromo-N-(3-chloropropyl)benzenesulfonamide technical grade,usp/ep/jp grade.


Related News: Both were randomised, double-blinded, placebo-controlled trials in patients with moderate to severe autoantibody-positive SLE who were receiving standard therapy. Phenyl-N-acetoxy-N-tert-butylcarbamat manufacturers ICER’s researchers used a two-year treatment horizon in their model but noted that it’s unclear how long patients are supposed to remain on these treatments. The model may not fully capture the challenges the disease presents to patients, ICER acknowledged. 1H-Indole-1-acetic acid, 5-[3-[4-(4-ethyl-2-oxazolyl)phenoxy]propoxy]- suppliers Officials did, however, acknowledge that there’s growing evidence an extra jab may enhance the antibody response in immunocompromised people. Some small studies suggest up to 50% of people with no antibody response after the authorized regimen of two mRNA jabs developed a response after an additional dose, said CDC’s Sara Oliver, M.D. piperazine-2,5-diyl-bis-methanol vendor & factory.